Shiro Fujita1,2, Katsuhiro Masago3, Eiichi Sasaki3, Satoshi Tsukushi4, Yoshitsugu Horio5, Hiroaki Kuroda6, Toyoaki Hida5. 1. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan; jp.shirofujita@gmail.com. 2. Department of Respiratory Medicine, Kobe Central Hospital, Kobe, Japan. 3. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. 4. Department of Orthopaedic Surgery, Aichi Cancer Center, Nagoya, Japan. 5. Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan. 6. Department of Thoracic Surgery, Aichi Cancer Center, Nagoya, Japan.
Abstract
BACKGROUND/AIM: The Archer FusionPlex platform is widely used for comprehensive fusion-gene detection in cancer tissues. This platform separately displays results for strong-evidence and weak-evidence fusion candidates (WEFCs). Distinctive fusion patterns are frequently found in the weak-evidence category and information about the patterns is clinically essential. PATIENTS AND METHODS: We describe the type and frequency of WEFCs observed using the FusionPlex Sarcoma Panel (S Panel) and the FusionPlex ALK, RET, and ROS1 ver2 Panel (ARR Panel). RESULTS: A total of 97 specimens were examined and 620 candidates were detected and categorized as WEFCs. A median of five WEFCs were detected per sample. In the S Panel group, there were 13 WEFCs with a frequency of more than 1%. In the ARR Panel group, a total of 16 WEFCs were detected with a frequency of more than 1%. CONCLUSION: Specific WEFCs were detected according to the panel selected. Copyright
BACKGROUND/AIM: The Archer FusionPlex platform is widely used for comprehensive fusion-gene detection in cancer tissues. This platform separately displays results for strong-evidence and weak-evidence fusion candidates (WEFCs). Distinctive fusion patterns are frequently found in the weak-evidence category and information about the patterns is clinically essential. PATIENTS AND METHODS: We describe the type and frequency of WEFCs observed using the FusionPlex Sarcoma Panel (S Panel) and the FusionPlex ALK, RET, and ROS1 ver2 Panel (ARR Panel). RESULTS: A total of 97 specimens were examined and 620 candidates were detected and categorized as WEFCs. A median of five WEFCs were detected per sample. In the S Panel group, there were 13 WEFCs with a frequency of more than 1%. In the ARR Panel group, a total of 16 WEFCs were detected with a frequency of more than 1%. CONCLUSION: Specific WEFCs were detected according to the panel selected. Copyright
Authors: Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le Journal: Nat Med Date: 2014-11-10 Impact factor: 53.440
Authors: Suk Wai Lam; Anne-Marie Cleton-Jansen; Arjen H G Cleven; Dina Ruano; Tom van Wezel; Karoly Szuhai; Judith V M G Bovée Journal: J Mol Diagn Date: 2018-08-20 Impact factor: 5.568
Authors: Theresa A Boyle; Katsuhiro Masago; Kim E Ellison; Yasushi Yatabe; Fred R Hirsch Journal: Clin Lung Cancer Date: 2014-10-24 Impact factor: 4.785